Yoon Pil Whan, Kim Hong Jin, Yoon Jae Youn, Moon Jun-Ki, Lee Sunhyung
Department of Orthopaedic Surgery, Seoul Now Hospital, Anyang, Gyeonggi, South Korea.
Department of Orthopaedic Surgery, Kyung-in Regional Military Manpower Administration, Suwon, South Korea.
J Orthop Surg Res. 2025 Apr 11;20(1):368. doi: 10.1186/s13018-025-05782-4.
Oxidised regenerative cellulose (ORC) is an absorbable haemostatic agent that acts independently on the blood coagulation mechanisms. Although ORC products have been used as adjuncts in various surgical procedures, their haemostatic effect, particularly the powder type (Surgicel-P), during primary total hip arthroplasty (THA) remains uncertain. This study aimed to evaluate the effectiveness and safety of ORC powder in patients undergoing primary THA.
This study included 279 patients who underwent primary THA between January 2022 and July 2024, and they were divided into two groups based on the use of ORC powder: the control (n = 138) and SC (SurgiCel group, n = 141) groups. Data on perioperative outcomes, including operative time, total blood loss (TBL), intraoperative blood loss (IBL), hidden blood loss (HBL), haemoglobin (Hb) drops, and complication rates over 3 months, were collected and compared between the two groups.
The mean IBL was significantly lower in the SC group (197.1 mL) than in the control group (243.5 mL) (P < 0.001). The total operative time (P = 0.465), procedure time (P = 0.117), TBL (P = 0.167), and HBL (P = 0.771) showed no significant differences. The mean postoperative Hb drop was significantly different between the control and SC groups (1.5 vs. 1.0 g/dL, P < 0.001). Similarly, the mean postoperative day 1 Hb drop was significantly lower in the SC group than in the control group (1.7 vs. 2.0 g/dL, P = 0.013). Complication rates showed no significant differences during the 3-month postoperative follow-up.
ORC powder significantly reduced IBL and postoperative Hb drops without any comparable complications in patients undergoing primary THA. These findings suggest that ORC powder is a safe and effective haemostatic agent during primary THA procedures, which may be a valuable adjuvant for reducing blood loss and potential to reduce blood transfusion requirements.
氧化再生纤维素(ORC)是一种可吸收的止血剂,其作用独立于血液凝固机制。尽管ORC产品已在各种外科手术中用作辅助药物,但其在初次全髋关节置换术(THA)中的止血效果,尤其是粉末型(Surgicel-P),仍不确定。本研究旨在评估ORC粉末在接受初次THA的患者中的有效性和安全性。
本研究纳入了2022年1月至2024年7月期间接受初次THA的279例患者,根据是否使用ORC粉末将他们分为两组:对照组(n = 138)和SC(SurgiCel组,n = 141)组。收集并比较两组围手术期结果的数据,包括手术时间、总失血量(TBL)、术中失血量(IBL)、隐性失血量(HBL)、血红蛋白(Hb)下降情况以及3个月内的并发症发生率。
SC组的平均IBL(197.1 mL)显著低于对照组(243.5 mL)(P < 0.001)。总手术时间(P = 0.465)、手术过程时间(P = 0.117)、TBL(P = 0.167)和HBL(P = 0.771)无显著差异。对照组和SC组术后平均Hb下降有显著差异(1.5 vs. 1.0 g/dL,P < 0.001)。同样,SC组术后第1天的平均Hb下降显著低于对照组(1.7 vs. 2.0 g/dL,P = 0.013)。术后3个月随访期间并发症发生率无显著差异。
ORC粉末显著减少了初次THA患者的IBL和术后Hb下降,且无任何可比的并发症。这些发现表明,ORC粉末在初次THA手术中是一种安全有效的止血剂,可能是减少失血和降低输血需求潜力的有价值辅助药物。